Bionano Genomics (NASDAQ:BNGO) Announces Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Bionano Genomics (NASDAQ:BNGO) announced its quarterly earnings data on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.09), FiscalAI reports. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%. The business had revenue of $8.28 million during the quarter, compared to analysts’ expectations of $8.44 million.

Here are the key takeaways from Bionano Genomics’ conference call:

• Usage and recurring consumables grew: Q3 revenue rose 12% year over year to $8.3 million, while flow-cell sales reached a quarterly record of 9,870, up 18%. Consumable revenue increased 24%, although software revenue fell 31% on fewer VIA licenses.
• Profitability metrics improved: Adjusted gross margin rose to 48% from 46% a year earlier, and adjusted operating expenses declined 9% to $8.8 million. Management said it expects to reach adjusted EBITDA neutrality by the end of 2027.
• 2026 guidance was reaffirmed: Bionano expects full-year revenue of $31 million to $33 million, representing 9%–16% growth, and said it expects to land near the midpoint. Management described its previously discussed 2027 revenue range as a vision rather than confirmed guidance.
• Clinical adoption and reimbursement support advanced: MolDx proposed Medicare coverage for OGM testing in hematologic cancers across jurisdictions representing 31 states, with a final determination still pending. New York approvals at University of Rochester Medicine and Memorial Sloan Kettering, along with new clinical studies, add to adoption evidence.
• Supply constraints are limiting near-term sales: Long lead times for critical components have kept Bionano from meeting strong customer demand. Management expects backorders to clear by year-end and plans to roughly double capacity by mid-2027, but those timelines remain forward-looking.

Bionano Genomics Stock Up 6.0%

Shares of NASDAQ BNGO traded up $0.07 during mid-day trading on Tuesday, reaching $1.23. The company had a trading volume of 566,594 shares, compared to its average volume of 442,303. Bionano Genomics has a twelve month low of $1.00 and a twelve month high of $2.23. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.96 and a current ratio of 2.48. The stock has a market capitalization of $17.20 million, a PE ratio of -0.41 and a beta of 1.73. The stock’s 50 day moving average is $1.37 and its 200-day moving average is $1.23.

Analyst Ratings Changes

Several equities analysts have weighed in on BNGO shares. Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd. Wall Street Zen raised shares of Bionano Genomics to a “hold” rating in a research report on Saturday, September 26th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bionano Genomics has a consensus rating of “Hold” and an average target price of $6.00.

Bionano Genomics Company Profile

Bionano Genomics, Inc. is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations. The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.